Fresenius Medical Care AG & Co. KGaA (FMS)
29.88
-0.04 (-0.12%)
USD |
NYSE |
May 23, 16:00
29.88
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.51B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -24.45% |
| Valuation | |
| PE Ratio | 17.08 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.8392 |
| Price to Book Value | 1.185 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.7093 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6518 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 47.71% |
News
Headline
Wire
Time (ET)
PR Newswire
04/13 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/02/2022 | -- | Results | Q2 2022 | -- | 0.45 | -- | |
| 08/02/2022 | -- | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | 0.36 | 0.28 | 26.22% | |
| 05/04/2022 | -- | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/22/2022 | -- | Results | Q4 2021 | 0.44 | 0.49 | -9.53% | |
| 02/22/2022 | 09:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/02/2021 | -- | Results | Q3 2021 | 0.54 | 0.51 | 5.79% | |
| 11/02/2021 | 10:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. |
| URL | https://www.freseniusmedicalcare.com |
| Investor Relations URL | https://www.freseniusmedicalcare.com/en/investors/investors-overview/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Aug. 02, 2022 |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 13, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.8101 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 1.790 |
| Yield to Sector | 1.234 |
| Yield to Industry | 1.125 |
| Last Dividend Amt. | 0.7093 |
| Dividend Frequency | Annually |
| Last Ex-Dividend Date | May. 13, 2022 |
| Yield (TTM) | 2.37% |
| Forward Yield | 2.37% |
| Payout Ratio | 45.37% |
| Cash Payout Ratio | 24.40% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 20, 2022.
Fundamentals
| Revenue (TTM) | 20.86B |
| Total Expenses (TTM) | 18.94B |
| Net Income (TTM) | 1.024B |
| Total Assets (Quarterly) | 38.76B |
| Total Liabilities (Quarterly) | 22.53B |
| Shareholders Equity (Quarterly) | 14.77B |
| Cash from Operations (TTM) | 2.873B |
| Cash from Investing (TTM) | -1.382B |
| Cash from Financing (TTM) | -1.468B |
Ratings
Profile
Edit
| Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. |
| URL | https://www.freseniusmedicalcare.com |
| Investor Relations URL | https://www.freseniusmedicalcare.com/en/investors/investors-overview/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Aug. 02, 2022 |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 13, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| FMS Tweets |